There are high unmet medical needs in the few established immunomodulatory therapies for Innovimmune’s core therapeutic areas within Autoimmune Diseases and Inflammation. The limited therapies available today are mostly biologics directed against cytokines, cytokine receptors and the T-cell/B-cell immune compartments. These treatment modalities however, have significant limitations related to inflexible drug delivery options, safety & toxicity (risk of opportunistic infection, cancer) complications, moderate-to-limited efficacy, and prohibitive costs which limit their long-term maintenance use and tolerability for the patients. The challenge in immunomodulatory drug development has been to selectively target a specific Mechanism of Action [MOA] that limit disease progression without the unwarranted toxicities due to non-specific generalized immunosuppression.

Despite the diverse clinical manifestations of these therapeutic areas of interest, they share a unique common disease pathogenesis characterized by organ & tissue damage arising from the dysregulated immune responses and production of critical cytokines & chemokines, and downstream signal transduction events. Oral small molecule-based therapies directed against these important biological targets are therefore being intensively sought, as it provide ease of administration and flexible drug delivery options ideal as new treatment intervention modalities in Autoimmune and Inflammatory Diseases. Innovimmune's goal is to discover and develop first-in-class NME immunotherapies against these attractive biological targets directed against the cytokine/chemokine network and signal transduction mechanisms that are selective and highly-specific to the overlapping disease pathways. We will focus our drug discovery and early drug development efforts by delivering novel treatments to our patients suffering from these debilitating diseases.